Contact information for researchers and applicants
Grant Management Team
If you have any questions, please contact our Grant Management Team. They are happy to help you with the administrational procedures regarding your grant application or current research project. They can also refer you to one of our Programme Coordinators who supervise our research projects by research theme.
T: +31 20 - 570 04 50
bestedingen@kwf.nl
Programme Coordinator Team
Jasmijn Span, MSc - Basic Research
Scientific research aimed at obtaining insight into the origin and progression of cancer, its (psychosocial) effects, as well as basic principles of prevention and treatment of cancer and relevant technological developments. Basic research does not directly focus on the possible application of this knowledge.
Christina Stangl, PhD - Basic Research
Scientific research aimed at obtaining insight into the origin and progression of cancer, its (psychosocial) effects, as well as basic principles of prevention and treatment of cancer and relevant technological developments. Basic research does not directly focus on the possible application of this knowledge.
Lenno Krenning, PhD - Basic Research
Scientific research aimed at obtaining insight into the origin and progression of cancer, its (psychosocial) effects, as well as basic principles of prevention and treatment of cancer and relevant technological developments. Basic research does not directly focus on the possible application of this knowledge.
Marion Scharpfenecker, PhD - Biomarkers
Biomarkers are characteristics that are objectively measured and evaluated as an indicator for cancer risk, the presence of a specific cancer or recurrent cancer, the stage or severity of a specific cancer, and how well the patient responds to therapeutic intervention(s).
Maud Plantinga, PhD - Biomarkers
Biomarkers are characteristics that are objectively measured and evaluated as an indicator for cancer risk, the presence of a specific cancer or recurrent cancer, the stage or severity of a specific cancer, and how well the patient responds to therapeutic intervention(s).
Sigrid Oomen, PhD - Interventive Devices
Treatment instruments to prevent or treat local-regional sites of cancer or precancerous lesions. The modalities may be delivered non-invasively (e.g. radiation therapy), minimally invasively (e.g.cryoablation, hyperthermia) or by open surgery (invasive).
Bas Pouw, PhD - Imaging
Scientific research into imaging includes various types of techniques to obtain detailed pictures of areas inside the body, such as magnetic fields (MRI), X-rays (CT), ultrasound (echography) and radioactive substances (PET) for functional imaging. Imaging is used to detect early stage cancer, diagnose disease, plan treatment or assess therapeutic response.
Willeke la Fontaine - Ros, PhD - Immunotherapy
Immunotherapy is a cancer treatment that helps the patient’s own immune system to recognize and destroy cancer. Examples are monoclonal antibodies (drugs that counteract immune suppression or mark cancer cells for destruction), cytokines (small proteins that regulate immune responses) and therapeutic vaccines.
Eveline Noteboom, PhD - Implementation
Research on methods to facilitate the implementation of concrete applications (with demonstrable added value compared to the current practice) into national oncology policy and practice. Focus on the actions of healthcare professionals and other stakeholders as a key variable in the sustainable implementation of evidence-based interventions.
Delphi Coppens, PhD - Cell & Gene Therapy
Cell therapy is the transfer of living cells into a patient to treat cancer. It usually involves immune cells that have been modified to recognize and destroy cancer cells (e.g. dendritic cell vaccination or CAR T-cell therapy). Gene therapy is transfering genetic material into a patient and alterating the genetic code to treat cancer.
Mai Tran, MSc - Infrastructure
Infrastructural initiatives provide services, resources and networks to support cancer research. These initiatives enable the research community to address specific research questions and thereby help accelerate and/or optimise the exploitation of results to the patients and public.
Maaike Kuijpers, MSc - Clinical trials
Clinical trials are research studies performed in people to find out if new diagnostic methods and treatments are safe and effective. KWF supports researchers in conducting their trials and disseminating and implementing their results.
Lotte Reinhoudt, MSc - Side effects & Research Methodology
This portfolio focusses on KWF-projects in which side effects of medical procedures (e.g. pharmacotherapy) are the primary outcome measure and/or in which innovative research methodologies are used.
Tessa Nauta, PhD - Agents
Drugs or biologicals used to prevent or inhibit the proliferation of cancerous cells. Examples of agents are small molecules, therapeutic enzymes and hormones.
Janneke van Doorn, MSc - Lifestyle and Exposure & Quality of Life
Lifestyle & Exposure is the influence of behaviour or exposure to exogenous factors on the development, recurrence, aggravation or prevention of (side effects of) cancer (treatment). Quality of life encompasses the psychological, social and societal impact of cancer. This includes anxiety, depression, relationship problems, return to work, the degree of independence and personal beliefs.
Linda Schoo, PhD - Quality of Care
Scientific studies aimed at providing the most appropriate care to all cancer patients in all regions through optimal availability and use of therapies. Patient-driven indicators and real world evidence are included in the shared decision making process where possible. The results contribute to the best fitted treatment strategy for each individual patient, to providing (health) care providers with the most recent insights, and to transparency about the quality of the care offered.
